MTOR and chronic myelogenous leukemia, BCR-ABL1 positive: Treatment with TQ in FLT3‐ITD positive MV4‐11 AML cells and BCR‐ABL positive K562 CML cells led to a dose‐ and time‐dependent reduction in cell proliferation, significant downregulation of PI3K, Akt, and mTOR, and an increase in PTEN expression at both mRNA and protein levels.